{"id":745005,"date":"2014-04-10T00:00:00","date_gmt":"2014-04-10T00:00:00","guid":{"rendered":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/mercks-investigational-chronic-hepatitis-c-combination-therapy-mk-5172-mk-8742-demonstrates-antiviral-activity-in-hard-to-cure-patients-with-hcv-genotype-1-infection\/"},"modified":"2023-03-22T00:04:56","modified_gmt":"2023-03-22T04:04:56","slug":"mercks-investigational-chronic-hepatitis-c-combination-therapy-mk-5172-mk-8742-demonstrates-antiviral-activity-in-hard-to-cure-patients-with-hcv-genotype-1-infection","status":"publish","type":"news_item","link":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/mercks-investigational-chronic-hepatitis-c-combination-therapy-mk-5172-mk-8742-demonstrates-antiviral-activity-in-hard-to-cure-patients-with-hcv-genotype-1-infection\/","title":{"rendered":"Merck\u2019s Investigational Chronic Hepatitis C Combination Therapy MK-5172\/MK-8742 Demonstrates Antiviral Activity in Hard-to-Cure Patients with HCV Genotype 1 Infection"},"content":{"rendered":"<p class=\"bwalignc\">       Clinical Findings Support Initiation of C-EDGE Phase 3 Program     <\/p>\n<p>WHITEHOUSE STATION, N.J.&#8211;(<a target=\"_blank\" href=\"http:\/\/www.businesswire.com\" rel=\"noopener\">BUSINESS WIRE<\/a>)&#8211;Merck (NYSE:MRK), known as MSD outside of the United States and Canada,<br \/>\n      today announced interim results from the ongoing <i>C-WORTHy<\/i> study,<br \/>\n      a multi-arm Phase 2 clinical trial evaluating the efficacy and safety of<br \/>\n      an all-oral, once-daily regimen combining MK-5172, an investigational<br \/>\n      hepatitis C virus (HCV) NS3\/4A protease inhibitor, and MK-8742, an<br \/>\n      investigational HCV NS5A replication complex inhibitor, among patients<br \/>\n      with chronic HCV Genotype 1 infection (GT1). Interim analysis of<br \/>\n      hard-to-cure<sup>1<\/sup> patients administered MK-5172\/MK-8742 with and<br \/>\n      without ribavirin (RBV) for 12 or 18 weeks showed sustained viral<br \/>\n      response<sup>2<\/sup> (SVR), 4 to 8 weeks after the completion of therapy<br \/>\n      (SVR4\/8):\n    <\/p>\n<ul>\n<li class=\"bwlistitemmargb\">\n        HCV GT1 infected, treatment-na\u00efve cirrhotic patients, MK-5172\/MK-8742<br \/>\n        treated &#8211; 97 percent (28\/29 and 29\/30) for 12 and 18 weeks, and<br \/>\n        MK-5172\/MK-8742 plus RBV &#8211; 90 percent (28\/31) and 97 percent (30\/31)<br \/>\n        for 12 and 18 weeks, respectively.\n      <\/li>\n<li class=\"bwlistitemmargb\">\n        HCV GT1 infected prior-null responder patients (with or without<br \/>\n        cirrhosis), MK-5172\/MK-8742 treated &#8211; 91 percent (30\/33) and 97<br \/>\n        percent (29\/30) for 12 and 18 weeks, respectively, and MK-5172\/MK-8742<br \/>\n        plus RBV treated 94 percent (30\/32) and 100 percent (32\/32) for the 12<br \/>\n        and 18 weeks, respectively.\n      <\/li>\n<li class=\"bwlistitemmargb\">\n        Treatment-na\u00efve, non-cirrhotic patients with HCV\/HIV co-infection,<br \/>\n        MK-5172\/MK-8742 treated for 12 weeks &#8211; 90 percent (26\/29) and<br \/>\n        MK-5172\/MK-8742 plus RBV for 12 weeks 97 percent (28\/29).\n      <\/li>\n<\/ul>\n<p>\n      These data were presented at the 49th Annual Meeting of the European<br \/>\n      Association for the Study of the Liver (EASL), also known as The<br \/>\n      International Liver Congress\u2122 2014 in London, UK.\n    <\/p>\n<p>\n      \u201cThere is still a need for further options for the most<br \/>\n      difficult-to-cure patients, including those with cirrhosis and HCV\/HIV<br \/>\n      co-infection,\u201d said Dr. Eric Lawitz, MD, vice president, Scientific and<br \/>\n      Research Development, The Texas Liver Institute, and clinical professor<br \/>\n      of medicine, University of Texas Health Science Center in San Antonio.<br \/>\n      \u201cThese findings provide additional clinical evidence regarding the<br \/>\n      potential of MK-5172\/MK-8742 in treating a broad spectrum of HCV<br \/>\n      patients.\u201d\n    <\/p>\n<p>\n      <i><b>C-WORTHy<\/b><\/i><b> Study Design<\/b>\n    <\/p>\n<p>\n      <i>C-WORTHy<\/i> is a randomized, dose-responsive, parallel-group,<br \/>\n      multiple-site, double-blind clinical trial comparing different patient<br \/>\n      populations exposed to different durations of treatment of MK-5172 (100<br \/>\n      mg once daily) in combination with MK-8742 (50 mg once daily) with or<br \/>\n      without RBV in subjects with chronic HCV infection. A total of 471<br \/>\n      patients with chronic HCV GT1 and HCV RNA levels of \u226510,000 IU\/mL were<br \/>\n      enrolled in <i>C-WORTHy<\/i> and randomized across 16 arms. These results<br \/>\n      examine hard-to-cure subpopulations, including treatment-na\u00efve patients<br \/>\n      with liver cirrhosis (12- and 18-week arms, with and without RBV),<br \/>\n      prior-null responder patients with and without cirrhosis (12- and<br \/>\n      18-week arms, with and without RBV) and patients with HIV\/HCV<br \/>\n      co-infection (12-week arms).\n    <\/p>\n<p>\n      <b>Key Findings for MK-5172\/MK-8742<\/b>\n    <\/p>\n<p>\n      Viral suppression (HCV RNA levels less than 25 IU\/mL) was demonstrated<br \/>\n      for treatment-na\u00efve patients with cirrhosis, prior-null responder<br \/>\n      patients with and without cirrhosis and HIV\/HCV co-infected patients by<br \/>\n      Treatment Week (TW)12. These levels were maintained at rates between 90<br \/>\n      and 100 percent across patient subgroups through the completion of<br \/>\n      dosing and at the four-week treatment follow-up time point (FU4).\n    <\/p>\n<table cellspacing=\"0\" class=\"bwtablemarginb\">\n<tbody>\n<tr>\n<td class=\"bwpadl0  bwvertalignt bwalignl\" colspan=\"9\">\n<p class=\"bwcellpmargin\">\n            <b>Table 1<\/b>\n          <\/p>\n<\/td>\n<td>\n        <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0  bwvertalignt bwalignl bwsinglebottom\" colspan=\"9\">\n<p class=\"bwcellpmargin\">\n            <b>Interim Analysis of the <i>C-WORTHy<\/i> Trial: Treatment-Na\u00efve,<br \/>\n            Cirrhotic Patients with HCV <\/b>\n          <\/p>\n<p class=\"bwcellpmargin\">\n            <b>GT1 Infection (Intention-to-Treat Analysis (ITT), Excluding<br \/>\n            Patients Yet to Reach FU4)<\/b>\n          <\/p>\n<\/td>\n<td>\n        <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0  bwvertalignb bwalignc bwdoublebottom\">\n          <b>Parameter<\/b>\n        <\/td>\n<td class=\"bwdoublebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwpadl0  bwvertalignb bwalignc bwdoublebottom\">\n<p class=\"bwcellpmargin\">\n            <br \/>\n            <b>MK-5172 + MK-8742 +<\/b><br \/><b>RBV<\/b><br \/><b>(12 Weeks)<\/b><br \/><b>(N<br \/>\n            = 31)<\/b>\n          <\/p>\n<\/td>\n<td class=\"bwdoublebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwpadl0  bwvertalignb bwalignc bwdoublebottom\">\n          <b>MK-5172 + MK-8742<\/b><br \/><b>(NO RBV)<\/b><br \/><b>(12 Weeks)<\/b><br \/><b>(N<br \/>\n          = 29)<\/b>\n        <\/td>\n<td class=\"bwdoublebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwpadl0  bwvertalignb bwalignc bwdoublebottom\">\n          <b>MK-5172 + MK-8742 +<\/b><br \/><b>RBV<\/b><br \/><b>(18 Weeks)<\/b><br \/><b>(N<br \/>\n          = 32)<\/b>\n        <\/td>\n<td class=\"bwdoublebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwpadl0  bwvertalignb bwalignc bwdoublebottom\">\n          <b>MK-5172 + MK-8742<\/b><br \/><b>(NO RBV)<\/b><br \/><b>(18 weeks)<\/b><br \/><b>(N<br \/>\n          = 31)<\/b>\n        <\/td>\n<td>\n        <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0  bwvertalignm bwalignl bwsinglebottom\">\n<p class=\"bwcellpmargin\">\n            <b>SVR4\/8, % (n\/m\u2020)<\/b>\n          <\/p>\n<\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignc bwsinglebottom\">\n          <b>90% (28\/31)<\/b>\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignc bwsinglebottom\">\n          <b>97% (28\/29)<\/b>\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignc bwsinglebottom\">\n          <b>97% (30\/31)<\/b>\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignc bwsinglebottom\">\n          <b>97% (29\/30)<\/b>\n        <\/td>\n<td>\n        <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0  bwvertalignb bwalignl bwsinglebottom\" colspan=\"9\">\n          <b>No SVR, % (n)<\/b>\n        <\/td>\n<td>\n        <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl4  bwvertalignm bwalignl bwsinglebottom\">\n          <b>Breakthrough<\/b>\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignc bwsinglebottom\">\n          <b>3% (1)<\/b>\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignc bwsinglebottom\">\n          <b>0% (0)<\/b>\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignc bwsinglebottom\">\n          <b>0% (0)<\/b>\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignc bwsinglebottom\">\n          <b>0% (0)<\/b>\n        <\/td>\n<td>\n        <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl4  bwvertalignm bwalignl bwsinglebottom\">\n          <b>Relapse<\/b>\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignc bwsinglebottom\">\n          <b>7% (2)<\/b>\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignc bwsinglebottom\">\n          <b>3% (1)<\/b>\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignc bwsinglebottom\">\n          <b>0% (0)<\/b>\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignc bwsinglebottom\">\n          <b>3% (1)<\/b>\n        <\/td>\n<td>\n        <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl4  bwvertalignm bwalignl bwsinglebottom\">\n          <b>Non-virologic Discontinuation<\/b>\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignc bwsinglebottom\">\n          <b>0% (0)<\/b>\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignc bwsinglebottom\">\n          <b>0% (0)<\/b>\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignc bwsinglebottom\">\n          <b>3% (1)<\/b>\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignc bwsinglebottom\">\n          <b>0% (0)<\/b>\n        <\/td>\n<td>\n        <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0  bwvertalignt bwalignl bwsinglebottom\" colspan=\"9\">\n<p class=\"bwcellpmargin\">\n            \u2020 m = patients who have reached the FU4 visits (all patients in<br \/>\n            the 12-week arms, and 61\/63 patients in the 18-week arms have<br \/>\n            reached FU4).\n          <\/p>\n<\/td>\n<td>\n        <\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<table cellspacing=\"0\" class=\"bwtablemarginb\">\n<tbody>\n<tr>\n<td colspan=\"9\">\n        <\/td>\n<td>\n          &nbsp;\n        <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0  bwvertalignb bwalignl\" colspan=\"9\">\n<p class=\"bwcellpmargin\">\n            <b>Table 2<\/b>\n          <\/p>\n<\/td>\n<td>\n        <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0  bwvertalignb bwalignl bwsinglebottom\" colspan=\"9\">\n<p class=\"bwcellpmargin\">\n            <b>Interim Analysis of the <i>C-WORTHy<\/i> Trial: Prior Null<br \/>\n            Responders (~50% Cirrhotics), <\/b>\n          <\/p>\n<p class=\"bwcellpmargin\">\n            <b>Cirrhotic Patients with HCV GT1 Infection (ITT, Excluding<br \/>\n            Patients Yet to Reach FU4)<\/b>\n          <\/p>\n<\/td>\n<td>\n        <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0  bwvertalignb bwalignc bwdoublebottom\">\n          <b>Parameter<\/b>\n        <\/td>\n<td class=\"bwdoublebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwpadl0  bwvertalignb bwalignc bwdoublebottom\">\n<p class=\"bwcellpmargin\">\n            <br \/>\n            <b>MK-5172 + MK-8742 +<\/b><br \/><b>RBV<\/b><br \/><b>(12 Weeks)<\/b><br \/><b>(N<br \/>\n            = 32)<\/b>\n          <\/p>\n<\/td>\n<td class=\"bwdoublebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwpadl0  bwvertalignb bwalignc bwdoublebottom\">\n          <b>MK-5172 + MK-8742<\/b><br \/><b>(NO RBV)<\/b><br \/><b>(12 Weeks)<\/b><br \/><b>(N<br \/>\n          = 33)<\/b>\n        <\/td>\n<td class=\"bwdoublebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwpadl0  bwvertalignb bwalignc bwdoublebottom\">\n<p class=\"bwcellpmargin\">\n            <b>MK-5172 + MK-8742 +<\/b><br \/><b>RBV<\/b><br \/><b>(18 Weeks)<\/b><br \/><b>(N<br \/>\n            = 33)<\/b>\n          <\/p>\n<\/td>\n<td class=\"bwdoublebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwpadl0  bwvertalignb bwalignc bwdoublebottom\">\n          <b>MK-5172 + MK-8742<\/b><br \/><b>(NO RBV)<\/b><br \/><b>(18 weeks)<\/b><br \/><b>(N<br \/>\n          = 32)<\/b>\n        <\/td>\n<td>\n        <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0  bwvertalignb bwalignl bwsinglebottom\">\n<p class=\"bwcellpmargin\">\n            <b>SVR4\/8, % (n\/m\u2020)<\/b>\n          <\/p>\n<\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignc bwsinglebottom\">\n          <b>94% (30\/32)<\/b>\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignc bwsinglebottom\">\n          <b>91% (30\/33)<\/b>\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignc bwsinglebottom\">\n          <b>100% (32\/32)<\/b>\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignc bwsinglebottom\">\n          <b>97% (29\/30)<\/b>\n        <\/td>\n<td>\n        <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0  bwvertalignb bwalignl bwsinglebottom\" colspan=\"9\">\n          <b>No SVR, % (n)<\/b>\n        <\/td>\n<td>\n        <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl4  bwvertalignb bwalignl bwsinglebottom\">\n          <b>Breakthrough<\/b>\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignc bwsinglebottom\">\n          <b>0% (0)<\/b>\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignc bwsinglebottom\">\n          <b>0% (0)<\/b>\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignc bwsinglebottom\">\n          <b>0% (0)<\/b>\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignc bwsinglebottom\">\n          <b>3% (1)<\/b>\n        <\/td>\n<td>\n        <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl4  bwvertalignb bwalignl bwsinglebottom\">\n          <b>Relapse<\/b>\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignc bwsinglebottom\">\n          <b>0% (0)<\/b>\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignc bwsinglebottom\">\n          <b>9% (3)<\/b>\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignc bwsinglebottom\">\n          <b>0% (0)<\/b>\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignc bwsinglebottom\">\n          <b>0% (0)<\/b>\n        <\/td>\n<td>\n        <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl4  bwvertalignb bwalignl bwsinglebottom\">\n          <b>Non-virologic Discontinuation<\/b>\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignc bwsinglebottom\">\n          <b>6% (2)<\/b>\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignc bwsinglebottom\">\n          <b>0% (0)<\/b>\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignc bwsinglebottom\">\n          <b>0% (0)<\/b>\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignc bwsinglebottom\">\n          <b>0% (0)<\/b>\n        <\/td>\n<td>\n        <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0  bwvertalignb bwalignl bwsinglebottom\" colspan=\"9\">\n          \u2020 m = patients who have reached the FU4 visits (all patients in the<br \/>\n          12-week arms, and 62\/65 patients in the 18-week arms have reached<br \/>\n          FU4).\n        <\/td>\n<td>\n        <\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<p>\n      The most common adverse events observed among treatment-na\u00efve patients<br \/>\n      with cirrhosis and prior-null responder patients with and without<br \/>\n      cirrhosis were fatigue (23% and 28%, respectively), headache (24% and<br \/>\n      24%, respectively), and asthenia (8% and 19%, respectively). The most<br \/>\n      common adverse events observed among HIV co-infected patients were<br \/>\n      headache (8%), asthenia (8%), fatigue (7%), and sleep disorder (7%).<br \/>\n      There were no early discontinuations due to drug-related adverse events<br \/>\n      and no clinically significant abnormalities observed in routine<br \/>\n      laboratory analysis of hematologic markers.\n    <\/p>\n<p>\n      <b>About Merck\u2019s Phase 3 HCV Program: <i>C-EDGE<\/i><\/b>\n    <\/p>\n<p>\n      Based on the results of the Phase 2 clinical program, Merck has<br \/>\n      initiated Phase 3 clinical trials for MK-5172\/MK-8742. The Phase 3<br \/>\n      program, called <i>C-EDGE<\/i>, will evaluate the safety and efficacy of<br \/>\n      MK-5172\/MK-8742 with and without ribavirin in various genotypes and<br \/>\n      across a broad range of patient populations with chronic HCV. Study<br \/>\n      cohorts will include: <i>C-EDGE TN<\/i> (GT1, GT4-6; treatment-naive \u00b1<br \/>\n      cirrhosis), <i>C-EDGE CO-INFXN<\/i> (GT1, GT4-6; treatment-naive \u00b1<br \/>\n      cirrhosis with HIV\/HCV co-infection), <i>C-EDGE RECOVERY<\/i> (GT1,<br \/>\n      GT4-6; treatment-naive \u00b1 cirrhosis; \u00b1 HIV\/HCV co-infection on opiate<br \/>\n      substitution therapy), and <i>C-EDGE TE<\/i> (GT1, GT4-6; prior failed<br \/>\n      treatment with peginterferon\/ribavirin; \u00b1 HIV\/HCV co-infection). Study<br \/>\n      information can be found at <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.clinicaltrials.gov&amp;esheet=51076832&amp;newsitemid=20150410005469&amp;lan=en-US&amp;anchor=www.clinicaltrials.gov&amp;index=1&amp;md5=63798aee59763616b19abecf32c15e07\" rel=\"nofollow\">www.clinicaltrials.gov<\/a>.\n    <\/p>\n<p>\n      <b>Merck\u2019s Commitment to HCV<\/b>\n    <\/p>\n<p>\n      For more than 25 years, Merck has been at the forefront of the response<br \/>\n      to the HCV epidemic. Merck employees are dedicated to applying their<br \/>\n      scientific expertise, resources and global reach to deliver healthcare<br \/>\n      solutions that support people living with HCV worldwide.\n    <\/p>\n<p>\n      <b>About Merck<\/b>\n    <\/p>\n<p>\n      Today&#8217;s Merck is a global healthcare leader working to help the world be<br \/>\n      well. Merck is known as MSD outside of the United States and Canada.<br \/>\n      Through our prescription medicines, vaccines, biologic therapies, and<br \/>\n      consumer care and animal health products, we work with customers and<br \/>\n      operate in more than 140 countries to deliver innovative health<br \/>\n      solutions. We also demonstrate our commitment to increasing access to<br \/>\n      healthcare through far-reaching policies, programs and partnerships. For<br \/>\n      more information, visit <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fvip2-msd.com\/merckcom-migrated&amp;esheet=51076832&amp;newsitemid=20150410005469&amp;lan=en-US&amp;anchor=vip2-msd.com\/merckcom-migrated&amp;index=2&amp;md5=2d162cc12c42e1a6353256445b15e36d\" rel=\"nofollow\">vip2-msd.com\/merckcom-migrated<\/a><br \/>\n      and connect with us on <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.twitter%2FMerck&amp;esheet=51076832&amp;newsitemid=20150410005469&amp;lan=en-US&amp;anchor=Twitter&amp;index=3&amp;md5=644a7629d5b71290dffee5201293fb74\" rel=\"nofollow\">Twitter<\/a>,<br \/>\n      <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.facebook.com%2FMerckBeWell&amp;esheet=51076832&amp;newsitemid=20150410005469&amp;lan=en-US&amp;anchor=Facebook&amp;index=4&amp;md5=72a90375559d6552f5a2c682133eac20\" rel=\"nofollow\">Facebook<\/a><br \/>\n      and <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.youtube.com%2FMerck&amp;esheet=51076832&amp;newsitemid=20150410005469&amp;lan=en-US&amp;anchor=YouTube&amp;index=5&amp;md5=ee3c52e87017ccdcba138b428a8c3a26\" rel=\"nofollow\">YouTube<\/a>.\n    <\/p>\n<p>\n      <b>Merck Forward-Looking Statement<\/b>\n    <\/p>\n<p>\n      This news release includes \u201cforward-looking statements\u201d within the<br \/>\n      meaning of the safe harbor provisions of the United States Private<br \/>\n      Securities Litigation Reform Act of 1995. These statements are based<br \/>\n      upon the current beliefs and expectations of Merck\u2019s management and are<br \/>\n      subject to significant risks and uncertainties. There can be no<br \/>\n      guarantees with respect to pipeline products that the products will<br \/>\n      receive the necessary regulatory approvals or that they will prove to be<br \/>\n      commercially successful. If underlying assumptions prove inaccurate or<br \/>\n      risks or uncertainties materialize, actual results may differ materially<br \/>\n      from those set forth in the forward-looking statements.\n    <\/p>\n<p>\n      Risks and uncertainties include but are not limited to, general industry<br \/>\n      conditions and competition; general economic factors, including interest<br \/>\n      rate and currency exchange rate fluctuations; the impact of<br \/>\n      pharmaceutical industry regulation and health care legislation in the<br \/>\n      United States and internationally; global trends toward health care cost<br \/>\n      containment; technological advances, new products and patents attained<br \/>\n      by competitors; challenges inherent in new product development,<br \/>\n      including obtaining regulatory approval; Merck\u2019s ability to accurately<br \/>\n      predict future market conditions; manufacturing difficulties or delays;<br \/>\n      financial instability of international economies and sovereign risk;<br \/>\n      dependence on the effectiveness of Merck\u2019s patents and other protections<br \/>\n      for innovative products; and the exposure to litigation, including<br \/>\n      patent litigation, and\/or regulatory actions.\n    <\/p>\n<p>\n      Merck undertakes no obligation to publicly update any forward-looking<br \/>\n      statement, whether as a result of new information, future events or<br \/>\n      otherwise. Additional factors that could cause results to differ<br \/>\n      materially from those described in the forward-looking statements can be<br \/>\n      found in Merck\u2019s 2013 Annual Report on Form 10-K and the company\u2019s other<br \/>\n      filings with the Securities and Exchange Commission (SEC) available at<br \/>\n      the SEC\u2019s Internet site (<a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.sec.gov&amp;esheet=51076832&amp;newsitemid=20150410005469&amp;lan=en-US&amp;anchor=www.sec.gov&amp;index=6&amp;md5=9dfc26685deaf0feed2625346d363616\" rel=\"nofollow\">www.sec.gov<\/a>).\n    <\/p>\n<p>\n      <sup>1<\/sup> Defined as treatment-na\u00efve patients with liver cirrhosis,<br \/>\n      prior-null responder patients with and without cirrhosis and patients<br \/>\n      with HIV\/HCV co-infection\n    <\/p>\n<p>\n      <sup>2 <\/sup>Defined as HCV RNA below the limit of quantification or<br \/>\n      below the limit of detection at the last visit on record \u2013 4, 8, 12, or<br \/>\n      24 weeks after the completion of therapy\n    <\/p>\n<\/p>\n<p><img decoding=\"async\" alt=\"\" src=\"\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20150410005469r1&amp;sid=hq1sc1&amp;distro=nx&amp;lang=en\"><span class=\"bwct31415\"><\/span><\/p>\n<p>       Merck<br \/>Media Contacts:<br \/>Caroline Lappetito, 267-305-7639<br \/>Sarra        Herzog, 201-669-6570<br \/>or<br \/>Investor Contacts:<br \/>Carol        Ferguson, 908-500-1101<br \/>Justin Holko, 908-423-5088     <\/p>\n","protected":false},"excerpt":{"rendered":"<p>Merck (NYSE:MRK), known as MSD outside of the United States and Canada, today announced interim results from the ongoing C-WORTHy study, a multi-arm Phase 2 clinical trial evaluating the efficacy and safety of an all-oral, once-daily regimen combining MK-5172, an investigational hepatitis C virus (HCV) NS3\/4A protease inhibitor, and MK-8742, an investigational HCV NS5A replication complex inhibitor, among patients with chronic HCV Genotype 1 infection (GT1). Interim analysis of hard-to-cure 1 patients administered MK-5172\/MK-8742 with and without ribavirin (RBV) for 12 or 18 weeks showed sustained viral response 2 (SVR), 4 to 8 weeks after the completion of therapy (SVR4\/8): HCV GT1 infected, treatment-na\u00efve cirrhotic patients, MK-5172\/MK-8742 treated &#8211; 97 percent (28\/29 and 29\/30) for 12 and 18 weeks, and MK-5172\/MK-8742 plus RBV &#8211; 90 percent (28\/31) and 97 percent (30\/31) for 12 and 18 weeks, respectively. HCV GT1 infected prior-null responder patients (with or without cirrhosis),<\/p>\n","protected":false},"template":"","meta":{"_acf_changed":false,"bdl_company_name":[],"bdl_item_external_link":[],"inpsyde_pem_expiration_date":[],"inpsyde_pem_expiration_action":[],"footnotes":""},"tags":[140,141,289],"class_list":["post-745005","news_item","type-news_item","status-publish","hentry","tag-hepatitis-c","tag-hepatitis-c-newsroom","tag-press-release"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.6 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Merck\u2019s Investigational Chronic Hepatitis C Combination Therapy MK-5172\/MK-8742 Demonstrates Antiviral Activity in Hard-to-Cure Patients with HCV Genotype 1 Infection - Merck.com<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/mercks-investigational-chronic-hepatitis-c-combination-therapy-mk-5172-mk-8742-demonstrates-antiviral-activity-in-hard-to-cure-patients-with-hcv-genotype-1-infection\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Merck\u2019s Investigational Chronic Hepatitis C Combination Therapy MK-5172\/MK-8742 Demonstrates Antiviral Activity in Hard-to-Cure Patients with HCV Genotype 1 Infection - Merck.com\" \/>\n<meta property=\"og:description\" content=\"Merck (NYSE:MRK), known as MSD outside of the United States and Canada, today announced interim results from the ongoing C-WORTHy study, a multi-arm Phase 2 clinical trial evaluating the efficacy and safety of an all-oral, once-daily regimen combining MK-5172, an investigational hepatitis C virus (HCV) NS3\/4A protease inhibitor, and MK-8742, an investigational HCV NS5A replication complex inhibitor, among patients with chronic HCV Genotype 1 infection (GT1). Interim analysis of hard-to-cure 1 patients administered MK-5172\/MK-8742 with and without ribavirin (RBV) for 12 or 18 weeks showed sustained viral response 2 (SVR), 4 to 8 weeks after the completion of therapy (SVR4\/8): HCV GT1 infected, treatment-na\u00efve cirrhotic patients, MK-5172\/MK-8742 treated - 97 percent (28\/29 and 29\/30) for 12 and 18 weeks, and MK-5172\/MK-8742 plus RBV - 90 percent (28\/31) and 97 percent (30\/31) for 12 and 18 weeks, respectively. HCV GT1 infected prior-null responder patients (with or without cirrhosis),\" \/>\n<meta property=\"og:url\" content=\"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/mercks-investigational-chronic-hepatitis-c-combination-therapy-mk-5172-mk-8742-demonstrates-antiviral-activity-in-hard-to-cure-patients-with-hcv-genotype-1-infection\/\" \/>\n<meta property=\"og:site_name\" content=\"Merck.com\" \/>\n<meta property=\"article:modified_time\" content=\"2023-03-22T04:04:56+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-content\/uploads\/sites\/152\/2022\/03\/Merck.png\" \/>\n\t<meta property=\"og:image:width\" content=\"3056\" \/>\n\t<meta property=\"og:image:height\" content=\"1380\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data1\" content=\"7 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/mercks-investigational-chronic-hepatitis-c-combination-therapy-mk-5172-mk-8742-demonstrates-antiviral-activity-in-hard-to-cure-patients-with-hcv-genotype-1-infection\\\/\",\"url\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/mercks-investigational-chronic-hepatitis-c-combination-therapy-mk-5172-mk-8742-demonstrates-antiviral-activity-in-hard-to-cure-patients-with-hcv-genotype-1-infection\\\/\",\"name\":\"Merck\u2019s Investigational Chronic Hepatitis C Combination Therapy MK-5172\\\/MK-8742 Demonstrates Antiviral Activity in Hard-to-Cure Patients with HCV Genotype 1 Infection - Merck.com\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/#website\"},\"datePublished\":\"2014-04-10T00:00:00+00:00\",\"dateModified\":\"2023-03-22T04:04:56+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/mercks-investigational-chronic-hepatitis-c-combination-therapy-mk-5172-mk-8742-demonstrates-antiviral-activity-in-hard-to-cure-patients-with-hcv-genotype-1-infection\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/mercks-investigational-chronic-hepatitis-c-combination-therapy-mk-5172-mk-8742-demonstrates-antiviral-activity-in-hard-to-cure-patients-with-hcv-genotype-1-infection\\\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/mercks-investigational-chronic-hepatitis-c-combination-therapy-mk-5172-mk-8742-demonstrates-antiviral-activity-in-hard-to-cure-patients-with-hcv-genotype-1-infection\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"News\",\"item\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news-archive\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Merck\u2019s Investigational Chronic Hepatitis C Combination Therapy MK-5172\\\/MK-8742 Demonstrates Antiviral Activity in Hard-to-Cure Patients with HCV Genotype 1 Infection\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/#website\",\"url\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/\",\"name\":\"Merck.com\",\"description\":\"Just another vip-msd.com site\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Merck\u2019s Investigational Chronic Hepatitis C Combination Therapy MK-5172\/MK-8742 Demonstrates Antiviral Activity in Hard-to-Cure Patients with HCV Genotype 1 Infection - Merck.com","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/mercks-investigational-chronic-hepatitis-c-combination-therapy-mk-5172-mk-8742-demonstrates-antiviral-activity-in-hard-to-cure-patients-with-hcv-genotype-1-infection\/","og_locale":"en_US","og_type":"article","og_title":"Merck\u2019s Investigational Chronic Hepatitis C Combination Therapy MK-5172\/MK-8742 Demonstrates Antiviral Activity in Hard-to-Cure Patients with HCV Genotype 1 Infection - Merck.com","og_description":"Merck (NYSE:MRK), known as MSD outside of the United States and Canada, today announced interim results from the ongoing C-WORTHy study, a multi-arm Phase 2 clinical trial evaluating the efficacy and safety of an all-oral, once-daily regimen combining MK-5172, an investigational hepatitis C virus (HCV) NS3\/4A protease inhibitor, and MK-8742, an investigational HCV NS5A replication complex inhibitor, among patients with chronic HCV Genotype 1 infection (GT1). Interim analysis of hard-to-cure 1 patients administered MK-5172\/MK-8742 with and without ribavirin (RBV) for 12 or 18 weeks showed sustained viral response 2 (SVR), 4 to 8 weeks after the completion of therapy (SVR4\/8): HCV GT1 infected, treatment-na\u00efve cirrhotic patients, MK-5172\/MK-8742 treated - 97 percent (28\/29 and 29\/30) for 12 and 18 weeks, and MK-5172\/MK-8742 plus RBV - 90 percent (28\/31) and 97 percent (30\/31) for 12 and 18 weeks, respectively. HCV GT1 infected prior-null responder patients (with or without cirrhosis),","og_url":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/mercks-investigational-chronic-hepatitis-c-combination-therapy-mk-5172-mk-8742-demonstrates-antiviral-activity-in-hard-to-cure-patients-with-hcv-genotype-1-infection\/","og_site_name":"Merck.com","article_modified_time":"2023-03-22T04:04:56+00:00","og_image":[{"width":3056,"height":1380,"url":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-content\/uploads\/sites\/152\/2022\/03\/Merck.png","type":"image\/png"}],"twitter_card":"summary_large_image","twitter_misc":{"Est. reading time":"7 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/mercks-investigational-chronic-hepatitis-c-combination-therapy-mk-5172-mk-8742-demonstrates-antiviral-activity-in-hard-to-cure-patients-with-hcv-genotype-1-infection\/","url":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/mercks-investigational-chronic-hepatitis-c-combination-therapy-mk-5172-mk-8742-demonstrates-antiviral-activity-in-hard-to-cure-patients-with-hcv-genotype-1-infection\/","name":"Merck\u2019s Investigational Chronic Hepatitis C Combination Therapy MK-5172\/MK-8742 Demonstrates Antiviral Activity in Hard-to-Cure Patients with HCV Genotype 1 Infection - Merck.com","isPartOf":{"@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/#website"},"datePublished":"2014-04-10T00:00:00+00:00","dateModified":"2023-03-22T04:04:56+00:00","breadcrumb":{"@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/mercks-investigational-chronic-hepatitis-c-combination-therapy-mk-5172-mk-8742-demonstrates-antiviral-activity-in-hard-to-cure-patients-with-hcv-genotype-1-infection\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/vip2-msd.com\/merckcom-migrated\/news\/mercks-investigational-chronic-hepatitis-c-combination-therapy-mk-5172-mk-8742-demonstrates-antiviral-activity-in-hard-to-cure-patients-with-hcv-genotype-1-infection\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/mercks-investigational-chronic-hepatitis-c-combination-therapy-mk-5172-mk-8742-demonstrates-antiviral-activity-in-hard-to-cure-patients-with-hcv-genotype-1-infection\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"News","item":"https:\/\/vip2-msd.com\/merckcom-migrated\/news-archive\/"},{"@type":"ListItem","position":2,"name":"Merck\u2019s Investigational Chronic Hepatitis C Combination Therapy MK-5172\/MK-8742 Demonstrates Antiviral Activity in Hard-to-Cure Patients with HCV Genotype 1 Infection"}]},{"@type":"WebSite","@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/#website","url":"https:\/\/vip2-msd.com\/merckcom-migrated\/","name":"Merck.com","description":"Just another vip-msd.com site","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/vip2-msd.com\/merckcom-migrated\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"}]}},"acf":{"news_item_workflow_id":"8e8bb741-d0a5-40d6-841f-a46c06af177d","news_item_aria_label":"","media_files":null,"document_path":"https:\/\/s2.q4cdn.com\/584635680\/files\/doc_news\/Mercks-Investigational-Chronic-Hepatitis-C-Combination-Therapy-MK-5172MK-8742-Demonstrates-Antiviral-Activity-in-Hard-to-Cure-Patient-7SAUK.pdf","file":""},"_links":{"self":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item\/745005","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item"}],"about":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/types\/news_item"}],"version-history":[{"count":0,"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item\/745005\/revisions"}],"wp:attachment":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/media?parent=745005"}],"wp:term":[{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/tags?post=745005"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}